Rose Bengal Disodium

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals is a US-based, clinical-stage biotech focused on developing accessible and affordable immunotherapies from its wholly-owned platform of halogenated xanthene small molecules. The company's lead asset, rose bengal disodium, is being explored through different formulations for a wide range of indications, positioning it as a versatile drug candidate. With a leadership team combining healthcare, finance, and scientific expertise, Provectus aims to advance its pipeline but faces the inherent risks of clinical development and capital-intensive biotech operations.

Therapeutic Areas